Friday, July 10, 2026

pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA

Iovance Biotherapeutics

Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S

825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
Status
Public
HQ
825 Industrial Rd, Suite 400, San Carlos, California 94070, US
Founded
2007
Employees
916
Programs
36
Drugs
26
Patents
94
Clinical program

IOV-MEL-301

Phase 3 · small molecule · Melanoma

IOV-MEL-301 for Melanoma is a Phase 3 program (small_molecule) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

Internal code IOV-MEL-301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Iovance Biotherapeutics B.V.
Phase
Phase 3
Modality
small_molecule
Indication
Melanoma
Status
active
Trials
1